| Basics |
Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. Its drug candidates include avapritinib, BLU 554, BLU-782 and BLU-667.
|
| IPO Date: |
May 1, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$8.28B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$1.47 | 2.36%
|
| Avg Daily Range (30 D): |
$1.16 | 1.15%
|
| Avg Daily Range (90 D): |
$1.65 | 1.80%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.48M |
| Avg Daily Volume (30 D): |
4.18M |
| Avg Daily Volume (90 D): |
2.02M |
| Trade Size |
| Avg Trade Size (Sh.): |
66 |
| Avg Trade Size (Sh.) (30 D): |
133 |
| Avg Trade Size (Sh.) (90 D): |
92 |
| Institutional Trades |
| Total Inst.Trades: |
6,524 |
| Avg Inst. Trade: |
$3.45M |
| Avg Inst. Trade (30 D): |
$6.02M |
| Avg Inst. Trade (90 D): |
$6.1M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
3 |
| Market Closing Trades |
| Avg Closing Trade: |
$5.59M |
| Avg Closing Trade (30 D): |
$17.96M |
| Avg Closing Trade (90 D): |
$14.6M |
| Avg Closing Volume: |
73.67K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-2.48
|
$.01
|
$-.8
|
|
Diluted EPS
|
$-2.48
|
$.01
|
$-.8
|
|
Revenue
|
$ 562.12M
|
$ 149.41M
|
$ 146.37M
|
|
Gross Profit
|
$ 542.35M
|
$ 146.61M
|
$ 138.92M
|
|
Net Income / Loss
|
$ -155.73M
|
$ .5M
|
$ -49.96M
|
|
Operating Income / Loss
|
$ -174.31M
|
$ -41.09M
|
$ -41.2M
|
|
Cost of Revenue
|
$ 19.77M
|
$ 2.8M
|
$ 7.45M
|
|
Net Cash Flow
|
$ 10.24M
|
$ 19.79M
|
$ 14.1M
|
|
PE Ratio
|
|
|
|
|
|
|
